By leveraging the protective effects of P6, there is hope for developing treatments that can mitigate the neurological impacts of autism, ultimately improving the quality of life for individuals with ASD
From facial applications to scalp and specialty-use formulations, our expanding GHK-Cu portfolio allows providers to align treatment approaches with individual patient needs
Our recommendations, I would be the first to admit, are not ideal
Compared with the results of prototype BPC157 in rats, the pharmacokinetic parameters of [ 3 H]BPC157 evaluated based on total radioactivity changed markedly, indicating the significant metabolism and decomposition process of BPC157 in vivo
Conservative combination protocol (if attempting) Rationale for conservative approach: No safety data available Both peptides slow gastric emptying significantly Risk of severe GI complications Start low, go slow principle Tirzepatide component: Follow standard FDA-approved titration Weeks 1-4: 2.5mg weekly Weeks 5-8: 5mg weekly Weeks 9-12: 7.5mg weekly Weeks 13-16: 10mg weekly Week 17+: 12.5mg weekly (or stay at 10mg) Some reach 15mg weekly (maximum) Cagrilintide component (reduced from standard): Start AFTER tirzepatide stabilized at therapeutic dose (week 13+) Week 13-16: 0.6mg weekly (lower than standard) Week 17-20: 1.2mg weekly Week 21-24: 1.8mg weekly (may be maximum tolerable) Consider 2.4mg only if tolerating perfectly Conservative dosing comparison: Why sequential is safer: Tirzepatide establishes baseline first Can attribute new side effects to cagrilintide Easier to manage one variable at a time Option to stop cagrilintide if intolerable Less overwhelming than both simultaneously Expected benefits: 18-25% total weight loss (conservative estimate) Potentially superior to tirzepatide alone (15-22%) But incremental benefit may be modest (3-5% additional) Use SeekPeptides to plan sequential peptide additions safely
